Bioblast Pharma

Hope should not be rare

Dana Gelbaum

Dana Gelbaum

Chief Commercial Officer

Dana Gelbaum joined Bioblast in November 2016, bringing expertise in developing commercial strategy of clinical stage investigational drugs for rare diseases. Ms. Gelbaum is also VP Global Marketing and Corporate Development at Chiasma (NASDAQ: CHMA), a biopharma company focused on improving the lives of patients with rare diseases, she is with Chiasma since 2009. Prior to Chiasma, she was Director of Business Development at Recoly N.V., a biotechnology company that developed product candidates to treat hemophilia A patients. Prior to that she an Associate at Johnson & Johnson Development Corporation (JJDC), Johnson & Johnson’s investment arm, focusing on investments in biopharmaceutical companies in Europe and medical device companies in Israel. Prior to JJDC, she was Associate in Ernst & Young Corporate Finance Life Science Department. Ms. Gelbaum received her M.Sc. and M.B.A. from Tel Aviv University. Ms. Gelbaum is the inventor 4 patents.